ArticleCancer discovery2023

Early Clinical Success of MTA-Cooperative PRMT5 Inhibitors for the Treatment of CDKN2A/MTAP-Deleted Cancers.

Kathleen M MulvaneyPubMed ↗Publisher ↗

No numbers read from the abstract.